The estimated Net Worth of Peter A. Thompson is at least $60.3 million dollars as of 27 December 2023. Peter Thompson owns over 1,546,347 units of Corvus Pharmaceuticals Inc stock worth over $1,207,920 and over the last 9 years he sold CRVS stock worth over $58,732,608. In addition, he makes $342,177 as Independent Director at Corvus Pharmaceuticals Inc.
Peter has made over 26 trades of the Corvus Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 1,546,347 units of CRVS stock worth $28,669,273 on 27 December 2023.
The largest trade he's ever made was buying 1,712,400 units of Corvus Pharmaceuticals Inc stock on 20 May 2016 worth over $17,843,208. On average, Peter trades about 266,473 units every 46 days since 2016. As of 27 December 2023 he still owns at least 264,315 units of Corvus Pharmaceuticals Inc stock.
You can see the complete history of Peter Thompson stock trades at the bottom of the page.
Dr. Peter Thompson M.D. serves as Independent Director of the Company. Dr. Thompson currently serves as a Private Equity Partner for OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as Venture Partner since joining in September 2010. Dr. Thompson has served as a director of Adaptimmune Therapeutics plc, a biopharmaceutical company, since September 2014. Dr. Thompson currently serves on the boards of directors of several private companies. He is a board-certified internist and oncologist and has served as Affiliate Professor of Neurosurgery at the University of Washington since January 2010. Dr. Thompson co-founded and served as the Chief Executive Officer of Trubion Pharmaceuticals, Inc., a biopharmaceutical company, from 2002 to 2009. He was a medical staff fellow at the National Cancer Institute from 1985 to 1992. Dr. Thompson holds a B.Sc. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.
As the Independent Director of Corvus Pharmaceuticals Inc, the total compensation of Peter Thompson at Corvus Pharmaceuticals Inc is $342,177. There are 7 executives at Corvus Pharmaceuticals Inc getting paid more, with Daniel Hunt having the highest compensation of $1,554,080.
Peter Thompson is 60, he's been the Independent Director of Corvus Pharmaceuticals Inc since 2014. There are 8 older and 9 younger executives at Corvus Pharmaceuticals Inc. The oldest executive at Corvus Pharmaceuticals Inc is Dr. Richard A. Miller M.D., 70, who is the Co-Founder, Pres, CEO & Chairman.
Peter's mailing address filed with the SEC is C/O CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME, CA, 94010.
Over the last 9 years, insiders at Corvus Pharmaceuticals Inc have traded over $52,808,904 worth of Corvus Pharmaceuticals Inc stock and bought 11,523,300 units worth $85,214,510 . The most active insiders traders include Holdings A/S Novo, Street Partners Llc Adams et Capital, Llc Eco R1. On average, Corvus Pharmaceuticals Inc executives and independent directors trade stock every 46 days with the average trade being worth of $1,530,854. The most recent stock trade was executed by William Benton Jones on 6 May 2024, trading 20,000 units of CRVS stock currently worth $34,600.
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Corvus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: